Biblio
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. N Engl J Med. 2024.
Inhibition of FGF23 is a therapeutic strategy to target hematopoietic stem cell niche defects in β-thalassemia. Sci Transl Med. 2023;15(698):eabq3679.
. Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia. Blood Rev. 2022:101039.
. .